<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751243</url>
  </required_header>
  <id_info>
    <org_study_id>ALODEPLETE</org_study_id>
    <nct_id>NCT01751243</nct_id>
  </id_info>
  <brief_title>Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies</brief_title>
  <official_title>Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre,
      prospective, of cohort of patients who will receive different doses of allo-depleted
      lymphocytes .

      This project joins in this pioneering worldwide initiative with its own technology based on
      the use of proteasome inhibitors in vitro, which advantages are, over other methods
      described, the continuing viability of regulatory T cells and the use of a product to
      generate allo-depletion that, contrary to those reported by other research groups, it does
      not pose problems from the point of view of its use or toxicity as we employ a drug widely
      used clinically by intravenous administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to determine the safety of transplantation of
      hematopoietic progenitors from haploidentical donor with in vitro allo-depleted lymphocyte
      infusion.

      Secondary objectives:

        -  To assess the immune reconstitution pre and post-infusion of allo-depleted lymphocytes.

        -  To analyze the incidence of infections (CMV and aspergillus) post-transplant.

        -  To analyze the impact of acute and chronic graft-versus-host disease (GVHD).

        -  To optimize the dose of allo-depleted lymphocytes to reconstitute an immune response
           against pathogens without causing GVHD.

        -  To assess the rate of graft and myeloid and platelet engraftment time.

        -  To assess the rate of relapses, event-free survival and overall survival. It is hoped to
           recruit 20 clinically evaluable patients for safety purpose.

      The inclusion period is not more than 2 ½ years. Study duration shall not exceed three years
      from the inclusion of the first patient. The minimum follow-up of patients is 6 months after
      transplantation.

      The first 5 patients (group 0) will receive haploidentical transplantation of hematopoietic
      progenitors without subsequent infusion of allo-depleted lymphocytes and then in cohorts of 3
      patients, infuse +4 post-transplant day at doses of: 1x105 cluster of differentiation 3
      (CD3)/kg(group 1), 3x105 CD3/kg (group 2), 5x105 CD3 / kg (group 3), 1x106 CD3/kg (group 4)
      and 3x106 CD3/kg (group 5).

      Donor: it is performed one leukapheresis at least 30 days (4 weeks) prior to the scheduled
      progenitors infusion (day 0), in order to obtain effector T cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events and serious adverse events after allo-depleted lymphocyte infusion in vitro.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Transplant-Related Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Group 0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Haploidentical transplantation of hematopoietic progenitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allo-depleted lymphocyte infusion</intervention_name>
    <description>Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Haploidentical transplantation of hematopoietic progenitors</intervention_name>
    <description>Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.</description>
    <arm_group_label>Group 0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients aged between 16 and 50 years.

          -  Diagnosed as Hematological malignancy candidates to allogeneic transplant lacking of
             related or unrelated suitable donor (is more than one Human leukocyte antigen (HLA)
             mismatched over 8 antigens) and who don't have a cord with an adequate cellularity.
             The minimum period of search to be able to include the patient in the trial, currently
             considering the medium to find a suitable donor to be 2 months, it is set to 10 weeks,
             although in specific situations in which the responsible physician considers that the
             patient has a high risk of relapse, it may be proceed with inclusion before that
             period. These cases will be assessed individually with the trial coordinator.

        Exclusion Criteria:

          -  General condition&gt; Eastern Cooperative Oncology Group (ECOG) scale 2.

          -  Left Ventricular ejection fraction (LVEF) &lt;39%.

          -  Diffusion capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC)
             &lt;39% of the theoretical values.

          -  Impaired liver function (total bilirubin higher than 2 mg / dL and / or transaminases
             higher than 3 times the normal maximum.

          -  Creatinine clearance &lt;50 mL / minute.

          -  Presence of symptomatic heart, liver cirrhosis or chronic active hepatitis.

          -  Active tuberculosis.

          -  Serious diseases which prevent chemotherapy treatments.

          -  Associated neoplasias (active neoplasias which, according to the opinion of the
             investigator and the sponsor, could jeopardize patient safety).

          -  Presence of associated psychiatric pathology.

          -  HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose-Antonio Perez-Simón, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Torres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucía Lopez-Corral, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Ángeles Cuesta, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Carlos Haya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Cardesa</last_name>
    <phone>0034 955019040</phone>
    <email>ana.cardesa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Torres, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mª Carmen Martín Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª Angeles Cuesta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mª Angeles Cuesta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Lopez-Corral, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Lopez-Corral, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose-Antonio Perez-Simón, MD, PhD</last_name>
      <phone>955 013261</phone>
    </contact>
    <investigator>
      <last_name>Jose-Antonio Perez-Simón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Andalusian Initiative for Advanced Therapies</description>
  </link>
  <link>
    <url>http://www.cabimer.es</url>
    <description>Andalusian Molecular Biology and Regenerative Medicine Centre</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

